$NSRX News

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

NSRX: First Half 2026 Financial Results

NSRX: First Half 2026 Financial Results

Nasus Pharma Announces Transition of Chief Financial Officer

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth

Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27

OTC Markets Life Sciences Investor Forum: Dan Teleman, CEO, and Eyal Rubin, SVP and CFO, of Nasus Pharma with Zacks SCR's John Vandermosten, CFA

NSRX: NS002 June KOL Event

Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)

Nasus Pharma Announces NS003 Trial Demonstrates Preclinical Pharmacokinetic Profile Comparable To IV

Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis

NSRX: Initiating Coverage – Sniffing Out a Better Solution

Nasus Pharma to Participate in Upcoming Investor Conferences

Nasus Pharma shares are trading lower after Citizens lowered its price target on the stock from $19 to $18.

Nasus Pharma shares are trading lower after Citizens lowered its price target on the stock from $19 to $18.